Lung Cancer Clinical Trials in Chicago

Showing 101-120 of 358 trials

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

NCT05363280

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .

Small Cell Lung Cancer

Advenchen Pharmaceuticals, LLC.36 participantsStarted Nov 2022

Birmingham, Alabama, United States • Chicago, Illinois, United States • St Louis, Missouri, United States +3 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE22.2 miles

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

NCT03907852

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.

MesotheliomaMesothelioma, MalignantMesothelioma; Pleura+8 more

TCR2 Therapeutics57 participantsStarted Apr 2019

San Francisco, California, United States • Miami, Florida, United States • Chicago, Illinois, United States +8 more locations

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Lung Cancer Trials in Other Cities

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Expanded Access of Sotorasib

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Other Conditions in Chicago